In this video interview, David Morton, PhD, director of biostatistics at Certara, explains how regulatory momentum is ...
As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more ...
The FDA has opened the door to the use of Bayesian statistical methods in clinical trials. The worry: Introducing subjectivity into what should be an objective process.
GlobalData on MSN
The Bayesian challenge: complexity that pays off
The FDA has released draft guidance on how sponsors can use Bayesian models for clinical trials.
Bayesian methods have emerged as a pivotal framework in the design and analysis of clinical trials, offering a systematic approach for updating evidence as new data become available. By utilising ...
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study We divided the borrowing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results